[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Niagen Bioscience Inc (NAGE)

Niagen Bioscience Inc (NAGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 278,754
  • Shares Outstanding, K 79,644
  • Annual Sales, $ 129,420 K
  • Annual Income, $ 17,380 K
  • EBIT $ 11 M
  • EBITDA $ 12 M
  • 60-Month Beta 2.08
  • Price/Sales 2.07
  • Price/Cash Flow 16.62
  • Price/Book 3.26

Options Overview Details

View History
  • Implied Volatility 134.36% (-33.37%)
  • Historical Volatility 62.73%
  • IV Percentile 71%
  • IV Rank 11.04%
  • IV High 789.28% on 02/18/26
  • IV Low 53.07% on 06/27/25
  • Expected Move (DTE 27) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 158
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 6,528
  • Open Int (30-Day) 5,835
  • Expected Range 3.50 to 3.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.00
  • Number of Estimates 2
  • High Estimate $0.02
  • Low Estimate $-0.01
  • Prior Year $0.04
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.35 +4.48%
on 06/08/26
4.04 -13.37%
on 05/26/26
-0.20 (-5.41%)
since 05/18/26
3-Month
3.35 +4.48%
on 06/08/26
5.12 -31.66%
on 05/04/26
-1.05 (-23.08%)
since 03/18/26
52-Week
3.35 +4.48%
on 06/08/26
14.69 -76.17%
on 06/30/25
-10.28 (-74.60%)
since 06/18/25

Most Recent Stories

More News
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will...

NAGE : 3.50 (+3.86%)
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen ® and advancing...

NAGE : 3.50 (+3.86%)
Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will...

NAGE : 3.50 (+3.86%)
Niagen Bioscience: Q1 Earnings Snapshot

Niagen Bioscience: Q1 Earnings Snapshot

NAGE : 3.50 (+3.86%)
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from...

NAGE : 3.50 (+3.86%)
Niagen Bioscience's Revenue Momentum Tells One Story, but Operating Profit Tells Another

Barchart Research What to Expect from NAGE Earnings NAGE Generated May 5, 2026 Current Price $4.82 EPS Estimate $$0.06 Consensus Rating Strong Buy Average Move 20.64% Niagen Bioscience's Revenue Momentum...

NAGE : 3.50 (+3.86%)
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

New telehealth platform introduces prescription-only Niagen At-Home Injection Kit, expanding access to pharmaceutical-grade NAD+ support for cellular and tissue health delivered directly to eligible patients'...

NAGE : 3.50 (+3.86%)
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plusâ„¢

Partnership unlocks Olympia’s established clinic network for Niagen Plus, expands pharmaceutical-grade Niagen supply chain, and brings liquid compounded vials to market

NAGE : 3.50 (+3.86%)
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference...

NAGE : 3.50 (+3.86%)
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

NR is the first among NR, NMN, and NAD+ to receive a pharmacopeial quality benchmark, reinforcing Niagen Bioscience’s leadership in NAD+ science and ingredient quality

NAGE : 3.50 (+3.86%)

Business Summary

Niagen Bioscience Inc. is a nicotinamide adenine dinucleotide science and healthy-aging research company. Niagen Bioscience Inc., formerly known as ChromaDex Corp., is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 3.68
2nd Resistance Point 3.61
1st Resistance Point 3.55
Last Price 3.50
1st Support Level 3.42
2nd Support Level 3.35
3rd Support Level 3.29

See More

52-Week High 14.69
Fibonacci 61.8% 10.36
Fibonacci 50% 9.02
Fibonacci 38.2% 7.68
Last Price 3.50
52-Week Low 3.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.